Related Experiment Video
Updated: Jan 4, 2026
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Exploring the Molecular Mechanisms Underlying the in vitro Anticancer Effects of Multitarget-Directed Hydrazone
Massimiliano Cuccioloni1, Laura Bonfili1, Valentina Cecarini1
1School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032, Camerino, Italy.
Abstract:
The molecular targets and the modes of action behind the cytotoxicity of two structurally established N,O- or N,N-hydrazone ruthenium(II)-arene complexes were explored in human breast adenocarcinoma cells (MCF-7) and paralleled in non-cancerous and cisplatin-resistant counterparts (MCF-10A and MCF-7CR respectively). Both complexes, [Ru(hmb)(L1)Cl] (1, L1=4-((2-(2,4-dinitrophenyl)hydrazono)(phenyl)methyl)-3-methyl-1-phenyl-1H-pyrazol-5-olate) and [Ru(cym)(L2)Cl] (2, L2=1-((3-methyl-5-oxo-1-phenyl-1H-pyrazol-4(5H)-ylidene)(phenyl)methyl)-2-(pyridin-2-yl)hydrazin-1-ide), reversibly interact with moderate-to-high affinity with a number of molecular targets in cell-free assays, namely serum albumin, DNA, the 20S proteasome and hydroxymethylglutaryl-CoA reductase. Most interestingly, only 2 readily crosses the cell membrane and preserves its binding/modulatory ability toward the targets of interest upon rapid cellular internalization. The resulting action at multiple levels of the cancer cascade is likely the cause for the selective sensitization of tumour cells to p27-mediated apoptotic death, and for the ability of 2 to overcome the drug resistance problem.
Insights
Ruthenium(II)-arene complexes show cytotoxicity in breast cancer cells. Complex 2 effectively targets cancer cells, overcoming drug resistance by inducing apoptosis.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Inorganic Chemistry
Background:
- Ruthenium(II)-arene complexes are investigated for anticancer properties.
- Understanding their molecular targets and mechanisms is crucial for drug development.
Purpose of the Study:
- To explore the cytotoxicity of two N,O- or N,N-hydrazone ruthenium(II)-arene complexes.
- To identify their molecular targets and modes of action in cancer cells.
- To assess their efficacy in cisplatin-resistant and non-cancerous cell lines.
Main Methods:
- Synthesis and characterization of two ruthenium(II)-arene complexes.
- In vitro cytotoxicity assays using human breast adenocarcinoma (MCF-7) cells.
- Parallel studies in non-cancerous (MCF-10A) and cisplatin-resistant (MCF-7CR) cells.
- Cell-free assays to determine interactions with molecular targets like albumin, DNA, proteasome, and reductase.
Main Results:
- Both complexes demonstrated reversible interactions with molecular targets in cell-free assays.
- Complex 2 exhibited efficient cell membrane penetration and maintained target-binding ability intracellularly.
- Complex 2 selectively sensitized tumor cells to p27-mediated apoptosis.
- Complex 2 demonstrated efficacy in overcoming cisplatin resistance.
Conclusions:
- Complex 2 possesses multi-level action within the cancer cascade, leading to selective tumor cell sensitization.
- Complex 2 shows promise in overcoming drug resistance in breast cancer treatment.
More Related Videos
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
10:51The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
Published on: April 10, 2015
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...